A higher body mass index attenuates the long-term HbA1c-lowering effects of liraglutide in type 2 diabetes patients treated using sulfonylurea-based therapy
Crossref DOI link: https://doi.org/10.1007/s13340-016-0269-8
Published Online: 2016-04-13
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Yamamoto, Takeshi
Fukui, Tomoyasu
Higuchi, Akiko
Ohara, Makoto
Hayashi, Toshiyuki
Hirano, Tsutomu
Text and Data Mining valid from 2016-04-13